Biocartis Group NV (FRA:8XB) ROCE %: -56.80% (As of Jun. 2023)


FRA:8XB Biocartis Group NV FRA:8XB
14 GF Score
Price €0.26
View Full Analysis

What is Biocartis Group NV ROCE %?

Biocartis Group NV FRA:8XB 14 ROCE % is -56.80% as of Jun. 2023. GuruFocus rates FRA:8XB with a GF Score™ of 14/100.

ROCE % measures how well a company generates profits from its capital. It is calculated as EBIT divided by Capital Employed, where Capital Employed is calculated as Total Assets minus Total Current Liabilities. Biocartis Group NV's annualized ROCE % for the quarter that ended in Jun. 2023 was -56.80%.

Biocartis Group NV  (FRA:8XB) ROCE % Explanation

ROCE % can be especially useful when comparing the performance of capital-intensive companies. Unlike ROE %, which indicates the profitability of Shareholders Equity, ROCE % also considers long-term debt in Capital Employed. This can be helpful when analyzing companies with significant debt, as the result is neutralized by taking debt into consideration.

Generally speaking, a higher ROCE % indicates a stonger profitability for a company. Moreover, it is important to look at the ratio from a long term perspective. Investors tend to favor companies with stable and rising ROCE % trend over those with volatile ones.

Biocartis Group NV ROCE % Related Terms

Biocartis Group NV ROCE % Historical Data

* Premium members only.

The historical data trend for Biocartis Group NV's ROCE % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Biocartis Group NV ROCE % Chart

Biocartis Group NV Annual Data
Trend Dec13 Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22
ROCE %
Get a 7-Day Free Trial Premium Member Only Premium Member Only -32.97 -31.33 -24.86 -43.05 -60.28

Biocartis Group NV Semi-Annual Data
Dec13 Jun14 Dec14 Jun15 Dec15 Jun16 Dec16 Jun17 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23
ROCE % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -40.46 -47.04 -51.22 -80.01 -56.80
FRA:8XB
14GF Score
Biocartis Group NV FRA:8XB
ROCE % is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Biocartis Group NV ROCE % Calculation

Biocartis Group NV's annualized ROCE % for the fiscal year that ended in Dec. 2022 is calculated as:

ROCE %=EBIT/( (Capital Employed+Capital Employed)/ count )
(A: Dec. 2022 )  (A: Dec. 2021 )(A: Dec. 2022 )
=EBIT/( ( (Total Assets - Total Current Liabilities)+(Total Assets - Total Current Liabilities) )/ count )
(A: Dec. 2022 )  (A: Dec. 2021 )(A: Dec. 2022 )
=-54.434/( ( (142.48 - 33.705) + (114.277 - 42.449) )/ 2 )
=-54.434/( (108.775+71.828)/ 2 )
=-54.434/90.3015
=-60.28 %

Biocartis Group NV's ROCE % of for the quarter that ended in Jun. 2023 is calculated as:

ROCE %=EBIT (1)/( (Capital Employed+Capital Employed)/ count )
(Q: Jun. 2023 )  (Q: Dec. 2022 )(Q: Jun. 2023 )
=EBIT/( ( (Total Assets - Total Current Liabilities)+(Total Assets - Total Current Liabilities) )/ count )
(Q: Jun. 2023 )  (Q: Dec. 2022 )(Q: Jun. 2023 )
=-43.282/( ( (114.277 - 42.449) + (112.981 - 32.409) )/ 2 )
=-43.282/( ( 71.828 + 80.572 )/ 2 )
=-43.282/76.2
=-56.80 %

(1) Note: The EBIT data used here is two times the semi-annual (Jun. 2023) EBIT data.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about ROCE % →
What does a ROCE % of -56.80% mean?
Biocartis Group NV (FRA:8XB) has a ROCE % of -56.80% as of Jun. 2023.
Is Biocartis Group NV's ROCE % too high?
Biocartis Group NV's current ROCE % is -56.80%. Overall, Biocartis Group NV has a GF Score™ of 14/100, reflecting its overall financial health beyond just this single metric.
How does Biocartis Group NV's ROCE % compare to TMO and DHR?
Biocartis Group NV's ROCE % of -56.80% can be compared against companies in the Medical Diagnostics & Research industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good ROCE % for a Medical Diagnostics & Research company?
A good ROCE % depends on the Medical Diagnostics & Research industry context. However, ROCE % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high ROCE % mean?
A high ROCE % can signal that a stock is expensive relative to its fundamentals. Biocartis Group NV's current ROCE % is -56.80%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Biocartis Group NV stock overvalued right now?
Biocartis Group NV (FRA:8XB) has a current ROCE % of -56.80%. The current ROCE % is -56.80%. Biocartis Group NV's overall GF Score™ is 14/100. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is ROCE % calculated?
ROCE % is calculated from a company's financial statements. For Biocartis Group NV (FRA:8XB), the current ROCE % is -56.80% as of Jun. 2023. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Biocartis Group NV Business Description

Address Generaal de Wittelaan 11 B, Mechelen, BEL, 2800
Biocartis Group NV is a commercial-stage molecular diagnostics company. It provides diagnostic solutions aimed at improving clinical practice for patients, clinicians, payers, and the industry. The firm has developed an Meet Idylla molecular diagnostic system for oncology and infectious disease segments.
14GF Score

Get the complete analysis for FRA:8XB

ROCE % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€0.26
Price